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OBJECTIVES We measured plasma atrial/brain natriuretic peptide (ANP/BNP) levels at rest and during
exercise and correlated the results with various clinical findings, particularly with myocardial
ischemia, in asymptomatic hypertrophic cardiomyopathy (HCM).
BACKGROUND In patients with HCM, ANP and BNP levels are elevated and exercise-induced myocardial
ischemia is common. However, it has not yet been elucidated how these levels at rest and their
change with dynamic exercise are related to ischemia.
METHODS Levels of ANP and BNP were measured at rest and at peak exercise during 99mTc-
tetrofosmin scintigraphy in 31 asymptomatic patients with non-obstructive HCM and in 10
control subjects.
RESULTS Levels of ANP and BNP at rest and the change of ANP and BNP levels (pg/ml) from rest
to exercise were significantly greater in HCM than in control subjects (ANP: rest, 53.2 
31.8 vs. 11.6  6.1; exercise, 114.5  74.8 vs. 28.3  23.4. BNP: rest, 156.7  104.1 vs.
9.8 9.6; exercise, 201.6 131.5 vs. 13.2 14.5). Septal perforator compression (SPC) and
exercise-induced ischemia were observed, respectively, in 20 (64.5%) and in 19 (61.3%)
patients with HCM. The increment of ANP during exercise was similar between HCM
subgroups with or without inducible ischemia. However, BNP levels at rest and BNP
increments during exercise were significantly greater in the HCM subgroup with inducible
ischemia than in the subgroup without (rest, 190.5  116.2 vs. 103.1  48.3; exercise,
250.5  142.2 vs. 124.2  58.6). Multiple logistic regression analysis revealed that SPC and
BNP levels at rest were independently associated with exercise-induced ischemia.
CONCLUSIONS Measurement of plasma BNP levels at rest may be useful in predicting silent myocardial
ischemia in HCM. (J Am Coll Cardiol 2002;39:1657–63) © 2002 by the American
College of Cardiology Foundation
Atrial natriuretic peptide (ANP) and brain natriuretic pep-
tide (BNP) play roles in fluid-electrolyte homeostasis (1,2),
the main secretion sites being the atria and ventricles,
respectively (2,3). Plasma ANP and BNP levels are elevated
in proportion to the severity of left ventricular (LV) systolic
and diastolic dysfunction and heart failure, and are useful in
evaluating prognosis (4–7). Recent studies clarified that
BNP levels were increased in hypertensive heart disease and
aortic stenosis, suggesting that BNP elevation is related to
LV hypertrophy (8,9). In addition, increased ANP and
BNP levels during dynamic exercise are associated with
myocardial ischemia in patients with angina pectoris (10).
The prognosis of asymptomatic patients with hypertro-
phic cardiomyopathy (HCM) in adults is relatively good,
compared with that of symptomatic patients (11). However,
exercise-induced myocardial ischemia has been demon-
strated in more than 50% of patients with asymptomatic
HCM (12), sometimes resulting in unfavorable events
(13,14). Brain natriuretic peptide levels in patients with
HCM, even if asymptomatic, were markedly elevated when
compared with various cardiac diseases, although little is
known concerning pathophysiologic significance of elevated
BNP levels (15,16). In the present study, we measured ANP
and BNP levels at rest and during exercise and correlated
the results with various clinical parameters including myo-
cardial ischemia.
METHODS
Study patients. We studied 31 patients with non-
obstructive HCM who were free from any cardiac symp-
toms (24 men, 7 women; mean age 54  10 years) and 10
age-matched control subjects (5 men, 5 women; mean age
54  5 years). The diagnosis of HCM was based on the
typical clinical, electrocardiographic and hemodynamic fea-
tures, with echocardiographic demonstration of a nondi-
lated, asymmetrically hypertrophied LV in the absence of
other cardiac or systemic diseases that can produce LV
hypertrophy (17). Patients with HCM were excluded from
this study when they had organic coronary stenosis, valvular
heart disease or systemic hypertension. In all the HCM
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patients studied, cardiac catheterization, echocardiography,
and exercise 99mTc-tetrofosmin scintigraphy were per-
formed. The control group consisted of asymptomatic
subjects who were consulted for a survey of minimal
electrocardiographic abnormality, but all of them demon-
strated normal echocardiograms and 99mTc-tetrofosmin
scintigrams. All the study subjects signed informed consent
forms before the study, and the study protocol was approved
by the research council of our institution.
Study protocol. Cardioactive medications (verapamil or
diltiazem) were discontinued for at least five half-lives
before the present study, in accordance with previous reports
(18,19).
ECHOCARDIOGRAPHIC STUDY. An Advanced Technology
Laboratory HDI 5000 ultrasound system was used for
echocardiographic analysis. After an overnight fast, patients
were subjected to evaluation of wall thickness, cavity size
and wall motion from multiple windows. Left ventricular
diastolic function was assessed by E/A ratio and isovolu-
metric relaxation time (IRT).
99mTc-TETROFOSMIN SCINTIGRAPHIC STUDY AND MEASURE-
MENT OF PLASMA ANP AND BNP LEVELS. Soon after the
echocardiographic study, 99mTc-tetrofosmin scintigraphy
was performed by a multistage bicycle ergometer exercise
test. At peak exercise, each subject intravenously received
370 MBq of 99mTc-tetrofosmin (Nihon Medi-Physics Co.,
Ltd, Nishinomiya, Japan) from the antecubital vein, and a
blood sample was simultaneously drawn from the contralat-
eral antecubital vein. Exercise was continued for an addi-
tional 1 min to allow adequate circulation of the isotope.
The exercise test was terminated when there was ischemic
ST segment depression 1 mm, excessive leg fatigue or
achievement of 100% of the maximal predicted heart rate.
Those who complained of chest pain or discomfort were
excluded from this study. Four hours later, blood samples
were collected and 740 MBq of 99mTc-tetrofosmin was
intravenously injected after 30 min bed rest. Image acqui-
sition at exercise and rest was each begun 30 min after the
injection of a tracer. A digital gamma camera (PRISM
2000XP, Marconi Medical Systems, Inc., Cleveland, Ohio)
equipped with a low-energy, high resolution parallel-hole
collimator was used for single photon emission computed
tomographic (SPECT) imaging.
The collected blood samples were transferred to dispos-
able tubes containing aprotinin (500 kallikrein inactivator
units/ml) and centrifuged at 3,000 rpm at 3°C for 10 min.
Plasma ANP and BNP levels were measured with a specific
immunoradiometric assay for alpha-human ANP and hu-
man BNP respectively using commercial kits (Shionoria kit,
Shionogi and Co., Ltd., Japan). Interassay coefficients of
variation for the ANP and BNP assays were 5.2% and 2.3%,
respectively.
IMAGE ANALYSIS. SPECT images were analyzed from two
viewpoints by three experienced nuclear cardiologists who
were unaware of angiographic and other clinical data:
regional perfusion abnormality and apparent LV cavity
dilation (LVCD). First, LV tomograms were divided into
13 segments. Short-axis slices at the basal and midventricu-
lar levels were each separated into six segments: anterosep-
tal, septal, posteroseptal, posterolateral, lateral and antero-
lateral. A vertical long-axis slice was used to evaluate the
apical portion of one segment. The degree of the tracer
uptake in these segments was semi-quantified using a
four-point scoring system: 0  normal, 1  slightly de-
creased, 2  moderately decreased, 3  complete defect.
Differences of opinion among the observers were resolved by
consensus. Scores for each region were averaged, and a
change of 1 or more from exercise to rest was defined as
reversible regional perfusion abnormality (18). Second, ap-
parent LVCD was quantified by the software we developed
previously (20,21). Thirty-six radii were generated at 10-
degree intervals from the center of the middle myocardial
images of the midventricular short-axis view. The area
surrounded by the 36 points of maximal count on each
radius was calculated in the exercise and rest images. The
exercise/rest ratio of the surface area was defined as the
transient dilation index (TDI). Abnormal apparent LVCD
was determined as mean  2 SD of the TDI in control
subjects. The intraobserver and interobserver analyses were
also examined for the reproducibility of TDI by two out of
three nuclear cardiologists. Exercise-induced myocardial
ischemia was defined as the presence of reversible regional
perfusion abnormality and/or abnormal apparent LVCD.
ANGIOGRAPHIC ASSESSMENT. Coronary angiography and
transcatheter measurement of hemodynamics were simulta-
neously evaluated within two weeks of the scintigraphic
study. Cineangiographic films were reviewed independently
by two cardiologists. Subjects showing atherosclerotic cor-
onary stenosis were excluded from this study. We also
investigated the prevalence and location of the systolic
compression of the septal branches. The degree of septal
perforator compression (SPC) of the left anterior descend-
ing artery was further classified according to the report by
Pichard et al. (22): grade 0 no systolic compression, grade
1  systolic disappearance of the distal third, grade 2 
disappearance of the distal two-thirds, grade 3 disappear-
ance of the entire septal perforator.
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
HCM  hypertrophic cardiomyopathy
IRT  isovolumetric relaxation time
LV  left ventricular/ventricle
LVCD  left ventricular cavity dilation
LVEDP  left ventricular end-diastolic pressure
sBP  increase of systolic blood pressure
SPC  septal perforator compression
SPECT  single photon emission computed tomography
or tomographic
TDI  transient dilation index
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STATISTICAL ANALYSIS. Data are expressed as mean  SD.
Differences between patients and control subjects or be-
tween the HCM subgroups were compared by the Mann-
Whitney U rank-sum test for unpaired data or by the
chi-square test for discrete variables. Two-way repeated
measures analysis of variance was used to evaluate the
increment of rate-pressure products and ANP and BNP
levels during exercise between patients with HCM and
control subjects or between the HCM subgroups. Linear
regression analysis was used to determine the correlations of
ANP and BNP levels at rest with echocardiographic and
hemodynamic variables. A multiple logistic regression anal-
ysis was performed to detect the influencing factors on
exercise-induced myocardial ischemia. The following vari-
ables were used as possible influencing factors: left atrial
dimension, LV wall thickness and cavity size, systolic and
diastolic functional indexes, the increase of systolic blood
pressure (sBP), SPC, electrocardiographic ST segment
depression and ANP and BNP levels at rest. Statistical
significance was defined as p  0.05.
RESULTS
Clinical features and plasma ANP and BNP levels.
Echocardiographically, ventricular septal thickness, poste-
rior wall thickness and left atrial diameter were significantly
greater in patients with HCM than in control subjects.
However, LV end-diastolic diameter and LV systolic and
diastolic indexes did not differ significantly. Exercise toler-
ance, the increment of rate-pressure products and sBP did
not differ significantly between the two groups. Levels of
ANP and BNP at rest were significantly greater in patients
with HCM than in control subjects (both p  0.0001). The
changes of both ANP and BNP levels during dynamic
exercise were more prominent in patients with HCM than
in control subjects (Table 1). In patients with HCM, both
ANP and BNP levels at rest did not show any significant
correlations with echocardiographic and hemodynamic vari-
ables (Table 2).
Scintigraphic findings (Fig. 1). Reversible regional per-
fusion abnormalities were observed in 16 patients with
HCM (51.6%). The prevalence (%) of ischemic changes in
each segment was 41.9 in anteroseptal, 9.7 in septal, 32.3 in
posteroseptal, 6.5 in posterolateral, 0 in lateral, 3.2 in
anterolateral and 16.1 in apical wall. Transient dilation
index was significantly greater in HCM patients than in
control subjects (1.21  0.27 vs. 1.00  0.06, p  0.004)
(Table 1). Abnormal apparent LVCD was identified in 14
patients with HCM (45.2%). Overall, exercise-induced
myocardial ischemia was found in 19 patients (61.3%). The
reproducibility for calculating TDI was excellent (r  0.99
for both intraobserver and interobserver analyses).
Table 1. Clinical Features and Plasma ANP and BNP Levels in HCM Patients and Control Subjects
HCM (n  31) Control Subjects (n  10) p Value
Echocardiogram
IVST (mm) 20  4 10  1 0.0001
PWT (mm) 11  2 9  1 0.002
LAD (mm) 44  5 35  2 0.0009
LVDd (mm) 45  6 45  4 0.80
FS (%) 42  7 38  7 0.18
E/A ratio 0.88  0.32 0.90  0.26 0.60
IRT (ms) 103  30 87  13 0.12
Exercise test
Exercise tolerance (watt) 95  28 105  23 0.23
Rest Peak Exercise Rest Peak Exercise
Rate-pressure products 10,397  2,601 23,249  6,101 11,188  2,236 26,041  7,173 0.35
ANP levels (pg/ml) 53.2  31.8 114.5  74.8 11.6  6.1 28.3  23.4 0.01
BNP levels (pg/ml) 156.7  104.1 201.6  131.5 9.8  9.6 13.2  14.5 0.007
sBP (mm Hg) 45  23 54  29 0.32
Scintigraphic test
TDI 1.21  0.27 1.00  0.06 0.004
ANP  atrial natriuretic peptide; BNP  brain natriuretic peptide; sBP  increase of systolic blood pressure; E/A ratio  ratio of early to late diastolic transmitral flow; FS 
fractional shortening; IRT  isovolumetric relaxation time; IVST  interventricular septal thickness; LAD  left atrial diameter; LVDd  left ventricular diastolic diameter;
PWT  posterior wall thickness; TDI  transient dilation index.
Table 2. Correlation Between ANP and BNP Levels at Rest
and Echocardiographic and Hemodynamic Variables
ANP BNP
r p Value r p Value
IVST 0.27 0.14 0.05 0.77
PWT 0.08 0.66 0.10 0.61
LAD 0.14 0.46 0.23 0.21
LVDd 0.01 0.60 0.17 0.37
FS 0.13 0.50 0.06 0.77
E/A ratio 0.30 0.10 0.32 0.08
IRT 0.05 0.79 0.09 0.63
LVEDP 0.08 0.71 0.004 0.99
sBP at rest 0.12 0.51 0.15 0.41
dBP at rest 0.29 0.11 0.30 0.10
HR at rest 0.06 0.76 0.09 0.62
dBP  diastolic blood pressure; HR  heart rate; sBP  systolic blood pressure.
Other abbreviations as in Table 1.
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Septal perforator compression (Fig. 2). Septal perforator
compression in the left anterior descending artery was
identified in 20 (64.5%) HCM patients: nine cases with
grade 1, eight with grade 2 and three with grade 3. Three of
these 20 patients with HCM (15.0%) demonstrated the
concurrence of SPC in the right coronary artery. Bridging of
the epicardial coronary artery was not found in any study
patient.
Clinical features in patients with HCM with or without
inducible myocardial ischemia (Table 3). We also com-
pared the clinical findings of HCM patients in terms of the
presence or absence of exercise-induced myocardial isch-
emia. Age, family history of HCM, echocardiographic
findings, rate-pressure products, sBP and ST depression
did not differ significantly between the two subgroups.
However, LV end-diastolic pressure (LVEDP) was greater,
and SPC was more frequent, in patients with HCM having
inducible ischemia. The increment of ANP during exercise
was similar between the two subgroups. However, the
HCM subgroup with inducible ischemia showed higher
BNP levels at rest (p  0.02) and more marked increment
of BNP levels during exercise (p  0.02) than did those
without.
Multiple logistic regression analysis. By multiple logistic
regression analysis, SPC and BNP levels at rest were
independently associated with exercise-induced myocardial
ischemia (p  0.03 and p  0.02, respectively).
DISCUSSION
Myocardial ischemia and SPC in HCM. Apparent
LVCD and regional perfusion abnormality have been re-
Figure 1. Exercise (top) and rest (bottom) tomographic images with 99mTc-tetrofosmin obtained from a patient with hypertrophic cardiomyopathy.
Apparent left ventricular cavity dilation is noted. Reversible regional perfusion abnormality is also observed at anteroseptal and posteroseptal areas of
junction and extended to the adjacent portions of anterior and posterior free walls.
Figure 2. Compression of septal branches of the left anterior descending coronary artery (LCA) (top) and posterior descending branch of the right coronary
artery (RCA) (arrows, bottom).
1660 Nakamura et al. JACC Vol. 39, No. 10, 2002
BNP and Silent Myocardial Ischemia in HCM May 15, 2002:1657–63
ported to be the characteristic SPECT findings of ischemia
in HCM (12,20,21,23,24). The present apparent LVCD is
considered to demonstrate exercise-induced subendocardial
ischemia, because this scintigraphic abnormality occurs in
the absence of any significant changes in end-diastolic
volume detected by radionuclide angiography, as previously
confirmed (20). Our software had excellent reproducibility,
and TDI enables us to quantify subendocardial ischemia
more reliably than does the usual method of judging visually
the presence or absence of apparent LVCD (18,24).
Subendocardial ischemia is related to elevated LV filling
pressures and impaired myocardial relaxation (23,25), and
LVEDP was actually higher in our HCM patients with
exercise-induced myocardial ischemia than in those with-
out. Unlike the results in a previous report (18), exercise-
induced myocardial ischemia in this study is not considered
related to abnormal blood pressure responses, because sBP
did not differ between HCM patients with exercise-induced
ischemia and those without. The difference may be attrib-
uted to the fact that our HCM patients were free from
cardiac symptoms and had relatively mild cardiac dysfunc-
tions.
Septal perforator compression was significantly more
frequent in HCM patients with exercise-induced myocar-
dial ischemia; this association was independent of other
factors. There are also several studies suggesting the contri-
bution of SPC to myocardial ischemia (19,26,27). Hirasaki
et al. (27) demonstrated that the septal perforators were
deviated toward the LV side in HCM and suggested that
SPC is caused by high intramural pressure. However, this
mechanism does not fully explain the discrepancy between
widespread 99mTc-tetrofosmin defects and the perfusion
territory of the septal perforators, as has been already
pointed out (12,19).
Myocardial disarray is associated with myocardial isch-
emia (28). Asynchrony of contraction and tension due to
disarray will impose abnormal mechanical force on the
muscle fibers and capillary beds, leading to perfusion disor-
der and ischemia at rest and to their further intensification
during exercise. Disarray is often observed in anteroseptal,
posteroseptal and apical walls of the LV (29). Marked
fascicle disarray is present in the anterior and posterior areas
of junction of the LV free wall and ventricular septum, with
fiber disarray extending to the adjacent portion of the free
walls and septum; however, disarray extends to the middle
portion of the septum to a far lesser degree (30). The
predominant area of 99mTc-tetrofosmin defects corresponds
well with the distribution of fascicle disarray and fiber
disarray. The rationale for the coincidence of disarray and
leftward deviation of the septal perforators has been de-
scribed elsewhere (27).
ANP and BNP in HCM. High ANP and BNP levels are
associated with diastolic dysfunction (6,7). In our HCM
patients also, diastolic dysfunction as suggested by impaired
LV relaxation and elevated LVEDP, though mild, may have
participated in ventricular wall stretch and BNP secretion.
Greater left atrial size, reflecting atrial wall stretch due to
diastolic dysfunction, may have promoted ANP release.
Cardiac hypertrophy was reported to be a strong stimulus to
the elevation of BNP levels (8,9,16,31). However, these
contributions are not considered large in the present study,
because both ANP and BNP levels at rest failed to demon-
strate any significant correlations with echocardiographic
and hemodynamic variables.
Table 3. Clinical Features of HCM Patients With or Without Inducible Myocardial Ischemia
With Exercise-Induced Myocardial Ischemia
(n  19)
Without Exercise-Induced Myocardial Ischemia
(n  12) p Value
Age (yrs) 53  10 57  10 0.29
Family history of HCM (n) 4 4 0.36
Echocardiogram
IVST (mm) 20  4 20  4 0.89
PWT (mm) 11  2 10  1 0.34
LAD (mm) 44  6 44  4 0.68
LVDd (mm) 46  6 43  6 0.27
FS (%) 42  7 42  7 0.97
E/A ratio 0.96  0.36 0.75  0.20 0.11
IRT (ms) 105  30 99  31 0.64
Hemodynamics
LVEDP (mm Hg) 16  7 11  4 0.02
Exercise Test Rest Peak Exercise Rest Peak Exercise
Rate-pressure products 10,373  2,453 23,284  6,465 10,436  2,932 23,194  5,755 0.94
ANP levels (pg/ml) 61.9  33.9 130.1  81.3 39.4  23.0 89.7  57.8 0.35
BNP levels (pg/ml) 190.5  116.2 250.5  142.2 103.1  48.3 124.2  58.6 0.02
 sBP (mm Hg) 45  24 45  23 0.95
ST depression 1 mm (n) 4 2 0.57
SPC (n) 15 5 0.04
HCM  hypertrophic cardiomyopathy; LVEDP  left ventricular end-diastolic pressure; SPC  septal perforator compression. Other abbreviations as in Figure 1.
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Immunohistochemical analysis disclosed that BNP im-
munoactivity in the ventricular wall was related to myocar-
dial disarray, myocyte hypertrophy and fibrosis in HCM
(32). 99mTc-tetrofosmin defects were predominantly located
in the area where fascicle or fiber disarray, myocyte hyper-
trophy and fibrosis are marked (30), suggesting that myo-
cardial ischemia due to these histological changes may
participate in the accelerated BNP secretion (28). Further-
more, in parallel with ischemia, abnormal stretch of some
muscle fibers due to the asynchrony of contraction and
tension in the disarrayed myocardium may stimulate the
ventricular BNP secretion at rest and during dynamic
exercise.
Unlike ANP levels, BNP levels at rest were higher, and
the increment of BNP levels on dynamic exercise was more
marked, in HCM patients with inducible myocardial isch-
emia than in those without. Together with SPC, a high
BNP level at rest was independently associated with
exercise-induced myocardial ischemia. Although the precise
mechanism explaining the relationship between the BNP
levels and myocardial ischemia remains obscure, these re-
sults present a significant clinical implication that BNP
levels at rest may be useful in predicting silent myocardial
ischemia.
Study limitations. We evaluated LV diastolic functions by
Doppler echocardiography just before the ergometer exer-
cise. There is, however, little evidence as to whether
Doppler indexes reflect diastolic function as accurately as
the invasive evaluation. (33). Trans-catheter measurement
of hemodynamics was not performed during ergometer
exercise, but we had obtained LVEDP during angiographic
study. Because the time lag was small, we may safely
consider that a high LVEDP was partly related to suben-
docardial ischemia and accelerated BNP secretion.
Conclusion. In patients with HCM, exercise-induced
myocardial ischemia was associated with higher BNP levels
at rest and more remarkable increase of BNP levels during
exercise. Evaluation of plasma BNP levels at rest may be
useful in predicting silent myocardial ischemia noninva-
sively.
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